Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study-Reference-Cited by-同舟云学术

Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study

Published:2016-07 Issue:1-3 Volume:174 Page:126-131
ISSN:0920-9964
Container-title:Schizophrenia Research
language:en
Short-container-title:Schizophrenia Research

Author:

Isitt John J.,Nadipelli Vijay R.,Kouassi Alex,Fava Maurizio,Heidbreder Christian

Funder

Indivior Inc.

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference27 articles.

1. Introductory Textbook of Psychiatry;Andreasen,2006

2. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone;Canuso;Int. Clin. Psychopharmacol.,2010

3. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia;de Haan;Pharmacopsychiatry,2008

4. Massachusetts General Hospital SAFER criteria for clinical trials and research;Desseilles;Harv. Rev. Psychiatry,2013

5. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-release formulation of risperidone;Gomeni;J. Clin. Pharmacol.,2013

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview of the currently available and emerging long-acting formulations of risperidone for schizophrenia and bipolar disorder;Expert Review of Neurotherapeutics;2024-07-23

2. An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients;Clinical Drug Investigation;2024-02-22

3. A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia;Brain Sciences;2023-11-10

4. Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient’s Subjective Quality of Life, Well-Being, and Satisfaction;Journal of Clinical Medicine;2023-11-08

5. New Antipsychotic Medications in the Last Decade;Current Psychiatry Reports;2021-11-29